Evolutionary prediction of medicinal properties in the genus <i>Euphorbia</i> L. by Ernst, Madeleine et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Evolutionary prediction of medicinal properties in the genus Euphorbia L.
Ernst, Madeleine; Saslis Lagoudakis, Haris; Grace, Olwen M.; Nilsson, Niclas; Simonsen,
Henrik Toft; Horn, James W.; Rønsted, Nina
Published in:
Scientific Reports
DOI:
10.1038/srep30531
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Ernst, M., Saslis Lagoudakis, H., Grace, O. M., Nilsson, N., Simonsen, H. T., Horn, J. W., & Rønsted, N. (2016).
Evolutionary prediction of medicinal properties in the genus Euphorbia L. Scientific Reports, 6, [30531].
https://doi.org/10.1038/srep30531
Download date: 03. Feb. 2020
1Scientific RepoRts | 6:30531 | DOI: 10.1038/srep30531
www.nature.com/scientificreports
Evolutionary prediction of 
medicinal properties in the genus 
Euphorbia L.
Madeleine Ernst1, C. Haris Saslis-Lagoudakis1, Olwen M. Grace2, Niclas Nilsson3, 
Henrik Toft Simonsen4, James W. Horn5 & Nina Rønsted1
The current decrease of new drugs brought to the market has fostered renewed interest in plant-based 
drug discovery. Given the alarming rate of biodiversity loss, systematic methodologies in finding 
new plant-derived drugs are urgently needed. Medicinal uses of plants were proposed as proxy for 
bioactivity, and phylogenetic patterns in medicinal plant uses have suggested that phylogeny can 
be used as predictive tool. However, the common practice of grouping medicinal plant uses into 
standardised categories may restrict the relevance of phylogenetic predictions. Standardised categories 
are mostly associated to systems of the human body and only poorly reflect biological responses to 
the treatment. Here we show that medicinal plant uses interpreted from a perspective of a biological 
response can reveal different phylogenetic patterns of presumed underlying bioactivity compared to 
standardised methods of medicinal plant use classification. In the cosmopolitan and pharmaceutically 
highly relevant genus Euphorbia L., identifying plant uses modulating the inflammatory response 
highlighted a greater phylogenetic diversity and number of potentially promising species than 
standardised categories. Our interpretation of medicinal plant uses may therefore allow for a more 
targeted approach for future phylogeny-guided drug discovery at an early screening stage, which will 
likely result in higher discovery rates of novel chemistry with functional biological activity.
Plants have played a central role in human health-care since ancient times1,2. Although the plant domain is widely 
regarded as natural capital with potential to yield new drugs, this potential is under threat due to the alarming bio-
diversity loss, with recent estimates indicating that every fifth plant species on earth is threatened with extinction3. 
Unlocking the potential of plants in health-care therefore urges for a time-efficient and systematic approach.
Following the assumption that plant-derived chemicals are constrained to evolutionary plant lineages4–6, 
phylogeny-guided approaches have been seen as one of the time-efficient and informed approaches to plant-based 
drug discovery7–14. Some of these approaches utilise information from ethnomedicine: the use of plants by 
humans as medicines15. Reports of medicinal plant uses are employed as a proxy for bioactivity and are superim-
posed on phylogenetic trees e.g.8,11,14. Evolutionary methodologies then predict potential bioactivity of different 
plant lineages, based on the distribution of medicinal plant use across the phylogeny.
One potential limitation of the phylogenetic approach lies in the classification of medicinal plant use. Prior to 
being analysed in a phylogenetic context, documented plant medicinal uses are collected and classified according 
to the diseases they are used to treat as typically done in ethnomedicinal research16. For this purpose, both inter-
nationally recognised medical standards such as the International Classification of Diseases (ICD; http://www.
who.int/classifications/icd/en/) of the WHO, as well as a classification system developed in the field of Economic 
Botany (Economic Botany Data Collection Standard, EBDCS17) are widely used16. Although these classification 
systems are useful to guarantee consistency, data exchange and comparability among different studies16,18, they 
have two major drawbacks. First, they do not fully capture the complexity and idiosyncrasy of local plant-based 
healthcare6,19,20. Second, and most important, they are based on categories reflecting systems of the human body 
(e.g. digestive system) or symptoms. Not only are classifications based on systems of the body affected or common 
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symptoms little informative for disease etiology21, but they also allow very little insight into the potential under-
lying biological activity of the medicinal plants. In recent years cellular and molecular mechanisms underlying 
diseases have been extensively studied22 and aided the discovery of disease etiology. We postulate that in a phy-
logenetic context a classification based on a biological response provoked by the treatment may reflect more 
accurately the cellular or molecular mechanisms underlying the disease’s treatment and thus provides a more 
accurate proxy of the biological activities of the plant-derived compounds and therefore enables a more accurate 
phylogenetic prediction of distinct biological activities triggered by the plants (Fig. 1).
Here, we investigate the influence of medicinal plant use classification in a phylogenetic context, using the 
genus Euphorbia L. (Euphorbiaceae) as an example. With about 2,000 recognized species23,24, Euphorbia is among 
the three largest genera of angiosperms, with a near-cosmopolitan distribution and remarkable morphological 
diversity, including annual herbs, succulents and large trees, united by a unique, flower-like inflorescence and 
often poisonous, milky latex24,25. The molecular phylogenetics of the genus has been extensively studied24,26–30 and 
a large compendium of data on the medicinal uses is available31. The diterpenoid ingenol mebutate, a chemical 
compound isolated from Euphorbia peplus L. is marketed as a drug for the treatment of actinic keratosis, a pre-
cancerous skin condition32. Nevertheless ingenol mebutate is only obtained in extremely low quantities from the 
plant, making its production inefficient33. Alternative sources are therefore desired and investigated33. Euphorbia 
exemplifies the need for a systematic approach to plant-based drug discovery: with approximately 5% of species 
in the genus chemically investigated34, how do we go about prioritizing which of the remaining 1,900 species to 
investigate?
We follow the core hypothesis that phylogenetic patterns in medicinal properties are underlied by similarities 
in phytochemical properties. We apply two interpretative approaches to the medicinal uses of Euphorbia – one 
following a standard classification system used in ethnomedicinal studies, the other aiming to identify plant uses 
modulating the inflammatory response. Inflammatory processes are highly relevant in the treatment of actinic 
keratosis by ingenol mebutate32. We scrutinize phylogenetic patterns in species recovered by both approaches and 
describe the influence of classification of medicinal plant use on the Euphorbia species identified for potential 
early drug discovery by selected phylogenetic measures. We refer to medicinal properties as properties described 
from ethnomedicinal research31. Data presented in this study are exclusively based on ethnomedicinal use reports 
of species of Euphorbia31 and do not include new chemical data on the genus Euphorbia. Instead, we refer to two 
extensive reviews on the chemical and pharmacological properties of species of the genus Euphorbia34,35. The 
context for the data presented in this study is therefore an assessment of an in vitro early stage screening in drug 
discovery, before parameters such as drugability, safety, formulation or comparative effectiveness of isolated com-
pounds are considered.
Results
We classified ethnomedicinal data using two different approaches: one that is used commonly in ethnomedicinal 
studies and one based on the biological response to the treatment. In specific, we identified plant uses modulating 
the inflammatory response. Inflammation is a prominent biological response to ingenol mebutate, which plays an 
important role in the treatment of actinic keratosis32,36. The first approach (EBDCS) is widely used in ethnome-
dicinal studies18 and classifies uses of plants into standardized descriptors and terms in hierarchical level states17. 
Level 1 states are subdivided into 13 categories (e.g. food, materials, fuels, medicines, vertebrate poisons etc.), 
whereas level 2 states break down level 1 states in more detail17. The level 2 states of the use category medicines 
Figure 1. Hypothetical distribution of medicinal plant uses across a phylogeny. (a) Plant medicinal 
uses as classified by the Economic Botany Data Collection Standard based on systems of the body (b) Same 
plant medicinal uses classified based on a biological response. When seeking lineages with potential agents 
modulating an inflammatory response, the classification in (a) is not informative. Instead, the classification in 
(b) allows us to identify clades (marked in red in (b)) that are overrepresented in species potentially modulating 
an inflammatory response. Icons: thenounproject.com.
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described by the EBDCS are mostly linked to systems of the body or symptoms of a disease, allowing only little 
insight into the disease’s cause or assumptions on a distinct biological activity or chemical nature of the medicinal 
plants. On contrary, our interpretation of plant medicinal uses gives a better insight into how the plant’s chemicals 
might interfere in the disease process (pharmacological effect37) and thus is a better proxy for the plant’s biological 
activity. Plant uses identified as modulating the inflammatory response were collected within a category we refer 
to as inflammatory response. We compared the category inflammatory response with the EBDCS categories inves-
tigating the effect of data organisation on evolutionary patterns relevant to early drug discovery.
First, using publicly available data, we produced the most comprehensive phylogenetic hypothesis of 
Euphorbia to date, including 560 Euphorbia species (>25% of the genus) representing all known subgeneric 
clades. In agreement with previous studies24,30 our topology (Supplementary Figure 1) confirms the presence 
of four subgeneric clades with posterior probability (PP) branch support values > 0.99 (except for subgenus 
Esula sensu lato PP = 0.90; subgenus Esula excluding E. lathyris, E. lagascae and E. phymatosperma PP = 0.99). 
Euphorbia subg. Esula (mainly herbaceous species with centre of diversity in temperate Europe29) is sister to 
the three remaining subgenera. Euphorbia subg. Athymalus (highly diverse succulent species with predomi-
nantly African distribution26,28) is sister to subgenera Euphorbia (most diverse species of the genus distributed 
across tropics and subtropics27) and Chamaesyce (diverse growth forms including many New World species26) 
(Supplementary Figure 1). With regard to relationships below the subgenus level, despite relatively low resolution 
as would be expected due to the use of only one marker (ndhF), no well supported (PP > 0.95) incongruences 
with previous studies were found26–29.
We then investigated the phylogenetic distribution of medicinal plants on the phylogeny of Euphorbia. We 
found that plants used medicinally in the genus are significantly phylogenetically clustered (median = 0.76, 
p(D < 1): ***, Table 1). The EBDCS level 2 state categories of medicines that showed weak to moderate phyloge-
netic signal included genitourinary system disorders and unspecified medicinal disorders (Table 2).
Of all EBDCS categories, the category inflammation is the most comparable to our interpretation of plant uses 
modulating the inflammatory response. However, in contrast to the EBDCS category inflammation, our category 
inflammatory response comprises not only plant species potentially causing an anti- but also a pro-inflammatory 
effect. In the interest of investigating differences resulting from the different classifications of medicinal plant 
uses, we subsequently compared the two inflammation-related categories. The category inflammatory response 
included 44 species, four times as many species as the EBDCS category inflammation (11 species; Fig. 2). There 
were also differences in the phylogenetic distribution of plants used for these two categories: A more than two-fold 
increase of the phylogenetic diversity index (PD) from the EBDCS category inflammation (median = 5.70, 7.40%; 
range = 4.71–6.79, 6.32–8.60%) to the category inflammatory response (median = 14.08, 18.36%; range = 11.96–
16.58, 16.78–20.03%) was observed. Given the differences in the groups of plant species identified by the differ-
ent inflammation-related categories, we further investigated whether plant species from these two categories 
come from the same lineages. We estimated the phylogenetic similarity between these two plant groups using 
the MNTD metric. The category inflammatory response showed no significant similarity to the EBDCS category 
inflammation (median = 0.40, p-value: ns, Table 3). It also showed no significant phylogenetic overlap with any 
of the other EBDCS level 2 state medicinal categories (Table 3). However, neither the EBDCS inflammation cat-
egory, nor the inflammatory response category showed significant phylogenetic clustering (median = 0.54 and 
0.88, p(D < 1): ns, Table 2). As a tentative approach to narrow down the number of species selected for bioactivity 
screening within the category inflammatory response, we identified nodes that are significantly overrepresented 
by species in this category (hot nodes8; Fig. 3). Hot nodes were mainly found within subgenera Chamaesyce and 
Euphorbia.
Discussion
Ethnomedicinal uses have inspired the discovery of many drugs in the past2,15,38. In recent decades, following the 
assumption that plant-derived chemicals are constrained to certain evolutionary plant lineages4–6, it was shown 
that plants used in ethnomedicine are not randomly distributed across taxonomic groups e.g.5,6,39. Taxonomic 
relationships were seen, therefore, as a way of predicting the occurrence and nature of useful chemicals in 
N Prevalence
D-statistic Phylogenetic signal
Median Range p(D < 1)a strengthb
Animal food 12 0.02 0.98 0.55–1.47 ns weak
Environmental uses 18 0.03 0.90 0.56–1.27 ns weak
Materials 15 0.03 0.88 0.61–1.21 ns weak
Medicines 65 0.12 0.76 0.65–0.88 *** weak
Non-Vertebrate poisons 9 0.02 0.85 0.39–1.57 ns weak
Social uses 8 0.01 0.82 0.15–1.51 ns weak
Vertebrate poisons 46 0.08 1.06 0.90–1.26 ns weak
Table 1. Phylogenetic signal per EBDCS level 1 state categories. Phylogenetic signal (D-statistic) on a 
randomly selected subset of 1,000 Bayesian trees within the 95% credible set of uses of Euphorbia31 classified 
into level 1 state categories according to the Economic Botany Data Collection Standard (EBDCS). Out  
of all level 1 state categories only medicines shows phylogenetic signal (in bold). N: Number of species.  
a* 95% p < 0.05; *** all p < 0.005. bweak: <90% p(D > 0) > 0.05; moderate: 90% p(D > 0) > 0.05; strong: 95% 
p(D > 0) > 0.05; very strong: all p(D > 0) > 0.05.
www.nature.com/scientificreports/
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plants5,6. More recent studies have built upon this idea and with increasingly robust molecular phylogenetic meth-
ods at hand have added to the taxonomy-oriented approaches to informed drug discovery7–14.
In this study, we explored evolutionary patterns of medicinal properties in Euphorbia. Based on the mecha-
nism of action of ingenol mebutate, we focused the investigation on described plant uses that possibly modulate 
an inflammatory response.
First, we looked at the phylogenetic distribution of medicinal plants on the phylogeny of Euphorbia. In 
agreement with previous studies on medicinal properties in other angiosperm lineages8,9,11,12,14, we found that 
Euphorbia species used medicinally are significantly phylogenetically clustered (Table 1). The EBDCS level 2 
state categories of medicines that showed weak to moderate phylogenetic signal included genitourinary system 
disorders and unspecified medicinal disorders (Table 2). Biological activities specific to systems of the body (such 
as the genitourinary system) can be of highly diverse nature, therefore assumptions on distinct biological actions 
N Prevalence
D-statistic Phylogenetic signal
Median Range p(D < 1)a strengthb
Abnormalities 12 0.02 0.83 0.48–1.20 ns weak
Digestive system disorders 26 0.05 0.78 0.51–1.04 ns weak
Genitourinary system 
disorders 9 0.02 0.35 −0.06–0.87 * moderate
Infections/infestations 21 0.04 0.82 0.50–1.15 ns weak
Inflammation 11 0.02 0.54 0.09–1.27 ns weak
Injuries 16 0.03 0.88 0.52–1.25 ns weak
Pain 15 0.03 0.78 0.43–1.19 ns weak
Respiratory system 
disorders 10 0.02 0.89 0.39–1.38 ns weak
Skin-/subcutaneous cellular 
tissue disorders 27 0.05 0.73 0.50–0.95 ns weak
Unspecified medicinal 
disorders 27 0.05 0.65 0.43–0.88 * weak
Inflammatory response 44 0.08 0.88 0.68–1.03 ns weak
No inflammatory response 12 0.02 0.85 0.49–1.29 ns weak
Unknown 23 0.04 1.05 0.77–1.37 ns weak
Table 2. Phylogenetic signal per EBDCS level 2 state categories medicines and the category inflammatory 
response. Phylogenetic signal (D-statistic) on a randomly selected subset of 1,000 Bayesian trees within 
the 95% credible set of uses of Euphorbia31 classified into level 2 state categories of medicines according to 
the Economic Botany Data Collection Standard (EBDCS) and the category inflammatory response. EBDCS 
categories genitourinary system disorders and unspecified medicinal disorders show phylogenetic signal (in bold), 
while the EBDCS category inflammation and the category inflammatory response don’t. N: Number of species. 
a* 95% p < 0.05; *** all p < 0.005. bweak: <90% p(D > 0) > 0.05; moderate: 90% p(D > 0) > 0.05; strong: 95% 
p(D > 0) > 0.05; very strong: all p(D > 0) > 0.05.
Figure 2. Phylogenetic distribution of species for (a) the Economic Botany Data Collection Standard (EBDCS) 
category inflammation and (b) the category inflammatory response. Red dots indicate species with documented 
use described in the category.
www.nature.com/scientificreports/
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or chemical underpinnings of the signal cannot be made. In contrast, neither the EBDCS inflammation category, 
nor the inflammatory response category showed significant phylogenetic clustering. Our rationale in this study 
was that classification of medicinal plant use based on the biological response to the treatment can uncover phy-
logenetic patterns that reflect more accurately the presence of certain chemical compounds. Our findings suggest 
N Prevalence
MNTD
Median Range p-value
Abnormalities 12 0.02 0.35 0.29–0.42 ns
Digestive system disorders 26 0.05 0.19 0.16–0.22 ns
Genitourinary system disorders 9 0.02 0.59 0.46–0.71 ns
Infections/infestations 21 0.04 0.14 0.12–0.18 ns
Inflammation 11 0.02 0.40 0.33–0.49 ns
Injuries 16 0.03 0.25 0.21–0.30 ns
Pain 15 0.03 0.29 0.24–0.34 ns
Respiratory system disorders 10 0.02 0.40 0.34–0.47 ns
Skin-/subcutaneous cellular tissue 
disorders 27 0.05 0.15 0.13–0.19 ns
Unspecified medicinal disorders 27 0.05 0.18 0.16–0.21 ns
Table 3. Phylogenetic similarity between the category inflammatory response and the EBDCS level 2 
state categories medicines. Mean nearest taxon distance (MNTD) between species in the Economic Botany 
Data Collection Standard (EBDCS) level 2 state medicines categories and the category inflammatory response. 
The category inflammatory response does not show significant phylogenetic similarity with any of the EBDCS 
categories and thus is sufficiently sensitive to highlight a different group of species, eventually reflecting 
unexplored medicinal potential not recovered by the EBDCS.
Figure 3. Hot nodes and corresponding clades of the category inflammatory response. Hot nodes (red dots) 
were identified by the nodesigl command in PHYLOCOM v4.2 on the majority consensus tree. Hot nodes 
indicate that the observed number of species in the category in that node is higher than expected by chance. 
Black dots indicate species with documented uses in the category inflammatory response. Photo: Mogens Trolle 
and Madeleine Ernst (Euphorbia pulcherrima).
www.nature.com/scientificreports/
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that inflammatory modulators are found in several Euphorbia lineages. This was recovered based on the EBDCS 
classification, but was even more pronounced by interpreting medicinal plant uses from a perspective of a biolog-
ical response. There are several potential explanations for this pattern. First, plant chemicals can be homoplasious, 
occurring across distantly related lineages40. This may be due to convergent evolution, recycling of chemicals from 
the environment by the plant e.g.41 or production of chemicals by endophytic fungi, as well as environmental 
and ecological effects on plant chemistry10,40,42. Although some structural types of Euphorbia diterpenoids, to 
which also ingenol mebutate belongs, and which most likely exhibit pro-inflammatory properties36, have been 
described as taxonomically significant for the genus43, their distribution across the phylogeny of Euphorbia may 
still be random, since their production may be more strongly influenced by some of the above named factors, or 
is not significantly related to the evolutionary history of the genus. Conservation of gene clusters associated with 
diterpenoid biosynthesis was reported at a high taxonomic level of the plant family Euphorbiaceae44. This suggests 
that the ability of diterpenoid production is present throughout the genus Euphorbia44. However, especially some 
members of Euphorbia subg. Chamaesyce have been reported as not containing Euphorbia specific diterpenoids34, 
potentially having the responsible genes silenced according to ecological needs40. Second, bioactivity might not 
be related to any phylogenetic patterns, since different chemical compounds from different biosynthetic routes 
may show the same or similar bioactivities45. For example, structurally different chemicals derived from unre-
lated natural sources have shown inhibition of the tumour necrosis factor-α, a pro-inflammatory cytokine, which 
regulates inflammation and related disorders45. Inflammatory modulators targeted by the inflammatory response 
category can be of different chemical structural classes and might therefore not follow a distribution associated 
with the phylogeny of the genus. It is therefore plausible that the category inflammatory response comprises a 
broad spectrum of different chemical structures, which are not associated to the phylogenetic relationships of the 
plants producing them. Third, there is inherent bias in the collection of data on medicinal use, as it is a subjective 
process with several restrictions, such as underrepresentation of certain languages and access to literature not 
available online. Only a large-scale chemical exploration of Euphorbia species would be able to tease apart the 
underlying causes of the phylogenetic pattern observed here.
When comparing the EBDCS category inflammation to the inflammatory response category we observed a 
more than two-fold increase of the phylogenetic diversity index (PD). Not only were more species included in 
the category inflammatory response, but also their distribution over the phylogeny was wider. Furthermore, the 
category inflammatory response showed no significant similarity to the EBDCS category inflammation, according 
to the MNTD metric. It also showed no significant phylogenetic overlap with any of the other EBDCS level 2 state 
medicinal categories. Our findings thus indicate that the category inflammatory response highlighted a different 
group of species, and may reflect unexplored medicinal potential not recovered by a standard method of classi-
fication such as the EBDCS. As a tentative approach to narrow down the number of species to be screened at an 
early stage of drug discovery within the category inflammatory response, we identified nodes that are significantly 
overrepresented by species in this category (hot nodes; Fig. 3). Hot nodes were mainly found within subgenera 
Chamaesyce and Euphorbia, which together comprise over half of the diversity in Euphorbia (about 1,200 species24). 
These two subgenera have not been as extensively studied chemically as subgenus Esula (the subject of 70% 
chemical studies to date34,35). Despite mentioned limitations, we were able to highlight specific lineages with 
a potential overrepresentation of chemical compounds modulating an inflammatory response in humans, and 
these highlighted lineages are poorly studied for their chemistry. Therefore, our approach shows potential for 
novel discoveries of pharmacologically relevant compounds from understudied plant lineages.
Although plant-derived chemicals play a relatively minor role in drug discovery in the pharmaceutical indus-
try nowadays, due to reasons related to the relatively labor-, time- and cost-intensive work with naturally derived 
chemicals, fear of duplication, intellectual property concerns or biodiversity conservation issues46–48 plant-derived 
drugs continue to be part of the list of essential medicines for priority diseases published by the WHO (WHO 
Model List of Essential Medicines, April 2015). Given the current decrease of new drugs brought to the market46, 
and the huge potential of plant-derived chemicals in providing medicinally relevant bioactivity, there is undoubt-
edly scope for innovation in identifying drug candidates. Our approach highlights clusters of species in Euphorbia 
subgenera Chamaesyce and Euphorbia, which compared to the European subgenus Esula, have largely been chem-
ically under-investigated. Out of a total of 91 Euphorbia species, which have been investigated for their chemistry 
and pharmacology34,35, there are only five species of Euphorbia subgenus Chamaesyce and 24 species of Euphorbia 
subgenus Euphorbia (based on recent taxonomic and molecular phylogenetic studies24,26–30,49). The remaining 62 
species form part of the European Euphorbia subgenus Esula.
Future large-scale chemical and pharmacological investigations of previously untested species will be able to 
show if selection based on a classification system reflecting the biological response to the treatment efficiently 
results in improved hit rates. The classification of plant medicinal uses proposed here was associated to the 
inflammatory response. The inflammatory response plays an important role in the efficacy of the treatment of 
actinic keratosis by ingenol mebutate, a diterpenoid isolated from Euphorbia peplus32,36. Despite its release to 
the market, ingenol mebutate is not sourced efficiently from Euphorbia peplus and alternative sources such as 
synthetic or biosynthetic approaches are being investigated33,44. Little is known about the biosynthetic pathway of 
Euphorbia diterpenoids and a synthetic route for ingenol mebutate production is not feasible yet33,44. Given the 
low percentage and uneven subgeneric distribution of species of the genus Euphorbia investigated chemically, it 
is likely to find species with higher production of ingenol mebutate or compounds with similar or other medici-
nally relevant bioactivity profiles. Based on our findings, chemical characterization and investigation of biological 
activities related to the inflammatory response of selected Euphorbia species will follow, using the evolutionary 
approach and methodologies of classification proposed in this study.
www.nature.com/scientificreports/
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Methods
Phylogenetic hypothesis. In this study, we produced a more densely sampled phylogenetic hypothesis of 
Euphorbia compiling DNA sequence data from the plastid marker ndhF from a series of studies focusing on sub-
genera of the genus26–29. Our matrix included sequences (1789 base pairs) of 560 Euphorbia species (>25% of the 
genus) representing all known subgeneric clades (Supplementary Table 1). To root the tree and allow comparison 
with previous studies24,26–30, exemplars of 15 related genera representing the remainder of the Euphorbiaceae fam-
ily were included as outgroup. Species names and corresponding GenBank accessions are listed in Supplementary 
Table 2. We produced a Bayesian phylogenetic hypothesis using the GTR + I + G model. All comparative phy-
logenetic analyses described below were performed on a randomly selected subset of 1,000 trees within the 95% 
credible set.
Medicinal uses of species of the genus Euphorbia. Information on uses of species of the genus 
Euphorbia was drawn from an extensive database31, including plants used medicinally as well as for other pur-
poses; such as animal food, environmental uses, materials, (non-) vertebrate poisons and social uses. The database 
contains over 1,000 use records referring to 156 Euphorbia species, of which 92 (63%) were included in our phy-
logenetic tree. The use records from the database were coded according to the Economic Botany Data Collection 
Standard (EBDCS)17, recommended by the Biodiversity Information Standards TDWG (http://www.tdwg.org).
Identifying Euphorbia uses modulating an inflammatory response. In the present study we argue 
that standard approaches to medicinal plant use classification used in previous studies are potentially misleading 
for predictive purposes in early drug discovery. We propose that, when studying medicinal plant uses in a phy-
logenetic context, a classification system that reflects the biological response to the treatment may reflect more 
accurately the cellular or molecular mechanism of the condition that a plant is used to treat and thus can reveal 
more successfully underlying biological activities and chemical properties. To illustrate this we used the EBDCS 
as an example. The level 2 states of the use category medicines described by the EBDCS17 are mostly linked to sys-
tems of the human body or symptoms of a disease, allowing only little insight into the disease’s cause or assump-
tions on a distinct biological activity or chemical nature of the medicinal plants. Here, we explore an alternative 
way of classifying diseases treated by Euphorbia species. We suggest that the proposed classification gives a better 
insight into how the plant’s chemicals might interfere in the disease process (pharmacological effect37) and thus is 
a better proxy for the plant’s biological activity than a classification based on systems of the body.
We focus on described plant uses that suggest to modulate an inflammatory response. The inflammatory 
response is a protective response, which eliminates offending agents of cell injury (e.g., microbes, toxins) and its 
consequences (e.g., necrotic cells and tissues). On the other hand, inflammatory reactions also underlie many 
pathologic conditions and they are thought to contribute to a variety of diseases such as metabolic, degenerative, 
or genetic disorders (e.g. type 2 diabetes, Alzheimer, cancer)50,51. Inflammatory modulators can thus interact at 
many different levels of the inflammatory cascade, including many different mechanisms of action. By targeting 
a biological response with many possible molecular mechanisms of action of the drug candidates we increase the 
possibility of discovering new chemical compounds in future early stage drug discovery screening approaches 
without being restricted to chemical compounds with very similar structures, which would most likely be tar-
geted by aiming for more specific mechanisms of action. Within the genus Euphorbia, almost 70% of all chem-
ical compounds described to date are new34. The chance of finding previously undiscovered compounds within 
Euphorbia is therefore considerably high. Also, an inflammatory response can be deducted relatively easily from 
ethnomedicinal descriptions, in comparison to more specific mode of actions. We were particularly interested 
in medicinal plant uses modulating the inflammatory response because inflammatory processes have shown 
relevance in the treatment of actinic keratosis by ingenol mebutate32. In vitro and in vivo studies of the molecular 
and cellular mode of action of the treatment showed that initial cell death is followed by a complex inflammatory 
response crucial for preventing tumor relapse and responsible for the high efficacy of the treatment32,36. Given 
that the inflammatory response, in particular, plays an important role in the efficacy of the treatment, we aimed to 
identify species of Euphorbia, suggesting the ability to modulate an inflammatory response in humans.
With special focus on whether the described treatment by the medicinal plant triggers an inflammatory 
response in humans, we investigated all records in the database of uses of Euphorbia. We looked for indica-
tions of the presence of a potential anti- or pro-inflammatory agent. We used the definitions of diseases given 
on the PubMed Health Diseases and Conditions Database52 and Dorland’s Illustrated Medical Dictionary53, 
which include either descriptions of diseases or their treatment. Use reports were thereafter classified into three 
categories: inflammatory response (treatment that can be related to an inflammatory response; 44 species), no 
inflammatory response (treatment that can not be related to an inflammatory response; 12 species), and unknown 
(description of medicinal use that contains insufficient information for classification; 23 species). Besides records 
describing medicinal uses of Euphorbia, we also included records of toxicity found in the EBDCS level 1 state 
category vertebrate poisons. Toxicity is separated from medicinality only by dosage and may therefore be a con-
vincing indicator of bioactivity54. An overview of the use data interpreted with the EBDCS categories and the 
inflammatory response categories is shown in Supplementary Tables 3 and 4.
Evolutionary patterns of medicinal properties in Euphorbia. Here, we explored whether our inter-
pretation of medicinal plant use can reveal different phylogenetic patterns, compared to a standard approach of 
classification. We performed three different comparative phylogenetic analyses.
First, we investigated the strength in phylogenetic signal of the EBDCS categories and the inflammatory 
response category using the D statistic55, a measure of phylogenetic signal, implemented by the function phylo.d 
in the R package caper56. Two p-values are calculated for the D statistic, p(D < 1) indicating whether the D metric 
is significantly smaller than 1, meaning that the trait (species’ medicinal properties) is not randomly distributed 
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over the phylogeny. The second p-value, p(D > 0) indicates whether the D metric is significantly greater than 0, 
meaning that the trait (species’ medicinal properties) has a significantly different distribution on the phylogeny 
from the standard Brownian model of evolution. The phylogenetic signal is considered strong if p(D < 1) < 0.05 
and p(D > 0) > 0.0555. In our study, phylogenetic signal was considered significant if >95% of the 1,000 trees 
showed a p(D < 1) value < 0.05 and the signal was considered strong if >95% of the 1,000 trees showed a p(D > 0) 
value > 0.05.
Second, we compared the phylogenetic diversity captured by plant species identified by the two different clas-
sification methods. To evaluate the phylogenetic diversity (PD) of species identified by the inflammatory response 
category and the EBDCS categories, we calculated the PD index (measuring the total branch length spanned by 
the tree of species in a given category) proposed by Faith57, and implemented in the function pd in the R package 
picante v.1.6-258. The PD index was expressed as absolute value as well as a percentage of the PD of the total phy-
logenetic tree. High PD percentage means that species included in this category are spread across the whole tree, 
while low percentage means that the species are found in only few, clustered parts of the tree.
Third, we investigated the overlap in the plant lineages identified by the two classification methods. To do that, 
we compared the phylogenetic similarity of the inflammatory response category and the EBDCS categories, by cal-
culating the mean nearest taxon distance (MNTD)59 – a measure showing the phylogenetic proximity of species 
between two categories on the tree - using the comdistnt function in the R package picante v.1.6-258. P-values for 
the MNTD were calculated by comparing the MNTD value between the inflammatory response category and an 
EBDCS category to 1,000 randomly generated categories of the same size within the species pool of the inflamma-
tory response category and the EBDCS category medicines. The two categories were considered phylogenetically 
significantly similar if at least 95% of the 1,000 trees showed a p-value < 0.05.
Further, as tentative approach to narrow down the number of species chosen for an early stage drug discov-
ery screening, we identified the position (nodes in phylogeny) of phylogenetic clustering for the inflammatory 
response category. We highlighted so-called “hot nodes” on the phylogeny, i.e. nodes that are significantly overrep-
resented by species in a given category8,11, using the nodesigl command in PHYLOCOM v4.259.
All analyses we describe were performed with in-house scripts in the R environment Version 3.0.3 (http://
www.R- project.org/), which are available in the Supplementary Information. Additional information on 
all method subsections is presented in Supplementary Methods. The alignment file as well as the set of 1,000 
Bayesian trees used for analysis was deposited on dryad (http://dx.doi.org/10.5061/dryad.s2df3).
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